Faricimab for DME: Results of phase 3 YOSEMITE and RHINE trials
Caroline Baumal, MD, highlights results from the Phase 3 YOSEMITE and RHINE trials, providing an overview of the efficacy, safety and durability of faricimab in DME.
Ophthalmology Times®' Sheryl Stevenson speaks with Caroline Baumal, MD, professor of ophthalmology, Tufts University School of Medicine; New England Eye Center (Boston, MA), on results from the Phase 3 YOSEMITE and RHINE trials, providing an overview of the efficacy, safety and durability of faricimab in diabetic macular edema (DME).
---
The American Society of Retina Specialists (ASRS) is hosting its 39th Annual Scientific Meeting from October 8-12, 2021, at the JW Marriott San Antonio Hill Country Resort and Spa in San Antonio, Texas.
Recent Videos
Related Content
